Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer

Executive Summary

National Cancer Institute's Phase II combo data for AstraZeneca's PARP inhibitor Lynparza and PD-L1 inhibitor Imfinzi are encouraging, but more research is needed to show a role for immunotherapy combinations in advanced prostate cancer.

Advertisement

Related Content

How The Prostate Cancer Market Will Look Over Next Decade

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel